Our strategies focus on developing new chemical entities for cancer and researching a new or better way to benefit patients. Now we obtain several patents for 505(b)(1) and 505(b)(2).

Meanwhile, our team is researching the mechanism of anti-proliferation in tumors by repositioning the new indications of FDA-approved drugs, for which we have obtained 505(b)(2) patents already.

The results provide advantages of those 505(b)(2) drugs as First-in-class medication in chemotherapy, shortening the development process and saving significant investment.

To increase the value and competitiveness of our products, our team is simultaneously developing new antiproliferative drug delivery, such as virus-like nanoparticles and nanoparticles.